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At present, the various mechanisms involved in 5-fluorouracil (5-FU)-correlated cardiotoxicity remain to be elucidated and a
universally accepted prophylaxis or treatment for this specific toxicity is not available. Although it may improve time to progression,
survival and clinical benefit, a 5-FU-based regimen usually has to be discontinued if a patient experiences cardiotoxicity. Here, we
describe our experience with three cases of 5-FU-associated cardiotoxicity. The angina-like pain that appeared approximately 95h
after beginning 5-FU therapy was apparently independent of the drug’s administration modality. In the two patients receiving 5-FU
12-h flat continuous infusion from 22.00 to 10.00h (5-FU 12-h c.i.) in combination with other drugs, the dose of 5-FU was reduced by
10–20% and patients received prophylactic transepidermal nitroglycerin. In the third patient, 5-FU administration modality was
changed and prophylactic therapy was not given. By taking these precautions, the patients no longer complained of anginal pain and
none of them discontinued chemotherapy.
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5-Fluorouracil (5-FU) is an active antimetabolite used in several
tumours, such as gastrointestinal tumours, in which the choice of
effective alternative drugs is limited (Kohne et al, 1998). The
spectrum of toxicities associated with 5-FU involves the gastro-
intestinal tract, the bone marrow, the skin and the central nervous
system. Last, but not the least, 5-FU may give cardiac toxicity that
is less familiar to physicians and this may present as precordial
pain, atrial arrhythmias, electrocardiogram (EKG) ST-T wave
changes, ventricular dysfunction and cardiogenic shock.
The overall incidence of 5-FU cardiotoxicity varies from 1.2 to
18% of patients and is usually underestimated, since silent EKG
alterations often occur (Klaus Becker et al, 1999). The different
mechanisms involved in 5-FU-associated cardiotoxicity are not yet
fully understood and no unequivocally effective prophylaxis or
treatment for this specific toxicity exists. Here, we describe three
cases of 5-FU-associated cardiotoxicity, its clinical management
and the prophylactic treatment used.
PATIENTS AND METHODS
Case 1
A 57-year-old male, with positive family history for acute
myocardial infarction (AMI) but with no history of cardiovascular
disease, came to our observation after undergoing an anterior
resection of the rectum for a stage III rectal–sigmoid adenocarci-
noma (RSA) (Table 1). Physical examination, chest X-rays, blood
pressure and EKG were all within normal limits. The patient
received four cycles of adjuvant chemotherapy with 5-FU
(370mgm
 2day
 1) and folinic acid (FA) (50mgtot
 1) i.v. for 5
days, every 3 weeks.
During adjuvant chemotherapy, disease progressed with liver
metastasis and the patient’s therapy was changed to irinotecan
(180mgm
 2) day 1 and 5-Fu 12-h flat continuous infusion from
22.00 to 10.00h (5-FU 12-h c.i.) (900mgm
 2day
 1) for 4 days,
every 2 weeks. Approximately 93h after starting the first cycle of
the second 5-FU regimen, the patient presented angina-like pain
that lasted a few minutes and disappeared with oral nitroglycerin.
The blood pressure was 160/115mmHg and the heart rate was 105
beatsmin 1 (b.p.m.). During the anginal attack, EKG recordings
and serum cardiac enzyme measurements were normal; therefore,
the same chemotherapy infusion schedule was continued, but the
dose of 5-FU was reduced to 800mgm
 2day
 1 and transepidermal
nitroglycerin prophylaxis was administered during 5-FU 12-h c.i.
The patient then received a further five cycles of this treatment
without any chest pain. Upon disease progression, the patient
received six cycles of oxaliplatin (100mgm
 2) day 1 and 5-FU 12-h
c.i. (800mgm
 2day
 1) for 4 days, every 2 weeks always associated
with prophylactic transepidermal nitroglycerin. No angina-like
syndrome recurred and no EKG changes were noted.
Case 2
A 65-year-old male with high blood pressure (HBP), diabetes and
gastritis came to our attention with abdominal lymphatic and
pulmonary metastases from an ampulla of Vater adenocarcinoma Received 27 November 2002; accepted 28 January 2003
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l(Table 1). He received one cycle of induction chemotherapy
containing cisplatin (CDDP) (100mgm
 2) day 1 and 5-FU 12-h c.i.
(1000mgm
 2day
 1) for 5 days, every 3 weeks. Approximately 95h
after beginning the first cycle of 5-FU infusion, the patient referred
several episodes of anginal pain, associated with sweating, that
disappeared with oral nitroglycerin. On day 5 of cycle I, the blood
pressure was 130/80mmHg, the heart rate was 104b.p.m. and the
EKG recorded shortly after pain remission showed ischaemic
alterations. The patient was admitted to the hospital and
immediately subjected to an echocardiogram that revealed a
reduction in inferior and posterolateral contractility and an altered
left ventricle diastolic release with an ejection fraction of 56%. The
EKG recorded the following day showed a T-alteration in
the anterolateral leads and a nonspecific ST segment elevation in
the inferior leads. At 4 days after the pain episode, the EKG showed
a T-alteration in the lateral leads, likely due to an AMI with
ischaemic alterations. The effort-EKG obtained on the same day
was interrupted at 80% of the maximum because ventricular
extrasystole bigeminis rised. The patient was subjected to CT-scan
for restaging of disease. This showed a 50% reduction of
pulmonary metastases and disappearance of abdominal lymphatic
metastasis. For this reason, the same chemotherapy infusion
schedule was continued, but the dose of 5-FU was reduced to
800mgm
 2day
 1. Transepidermal nitroglycerin was administered
during 5-FU infusion and chemotherapy was administered while
the patient recovered at the hospital. The dose of 5-FU for the
cycles thereafter was increased to 900mgm
 2day
 1 with trans-
epidermal nitroglycerin administration during 5-FU infusion. The
patient received a further four cycles of this treatment, in an
outpatient setting, and no longer complained of anginal pain.
Case 3
A 70-year-old female with HBP presented at our hospital with stage
II RSA (Table 1). She received three cycles of adjuvant
chemotherapy with bolus 5-FU (370mgm
 2day
 1) and FA
(50mgtot 1day
 1) for 5 days every 3 weeks. On the third cycle,
approximately 98h after starting 5-FU administration, the patient
presented a transient angina-like pain with dyspnoea that
disappeared with oral nitroglycerin. The EKG did not reveal
specific changes, plasma cardiac enzymes and the effort-EKG were
normal. 5-Fluorouracil therapy was not discontinued but the
schedule was modified to 5-FU 450mgm
 2 week
 1 and FA
100mgtot
 1week
 1 for 14 weeks; although transepidermal nitro-
glycerin prophylaxis was not given during 5-FU administration,
the patient no longer complained of anginal pain.
DISCUSSION
Relatively S-phase specific, 5-FU is a synthetic pyrimidine
antimetabolite drug that has been used as a cytostatic agent in
the treatment of various solid malignant tumours (adenocarcino-
mas, squamous cell cancer). The antitumour activity of 5-FU is
Table 1 Clinical and pathological features of patients
Case 1 Case 2 Case 3
Familiarity AMI — —
Age 57 65 70
Clinical history — HBP, diabetes, gastritis HBP
Tumour size RSA Ampulla of Vater RSA
Phase Metastatic Metastatic Adjuvant
Adjuvant therapy No No Yes
Type — — 5-FU
Procedure — — Bolus
Advanced therapy Yes Yes No
Type CPT11/5-FU CDDP/5-FU —
Procedure Bolus/continuous infusion Bolus/continuous infusion —
Symptom Chest pain Chest pain Chest pain
Duration Few minutes 5min Few minutes
Cycle 11 11 31
Day 41 41 41
Therapy Yes Yes Yes
Type Nitroglycerin Nitroglycerin Nitroglycerin
Examinations Yes Yes Yes
EKG Negative Ischaemic alteration Negative
EchoCG No Reduction of contractility No
Enzymes Negative Not done Negative
Effort-EKG No Ventricular extrasystole Negative
Other cycles Yes Yes Yes
Number 5 6 3
Procedure Bolus/continuous infusion Bolus/continuous infusion Bolus
Therapy Nitroglycerin/dose reduction of 5-FU Nitroglycerin/dose reduction of 5-FU Weekly
therapy
Other symptoms No No No
Other chemotherapy Yes No No
Type OXP/5-FU — —
Procedure Bolus/continuous infusion — —
Symptoms No — —
Other cycles Yes — —
Number 6 — —
Procedure Bolus/continuous infusion — —
Therapy Nitroglycerin — —
AMI¼acute myocardial infarction; CPT11¼irinotecan; EKG¼electrocardiogram; echoCG¼echocardiogram;
CDDP¼cisplatin; OXP¼oxaliplatin; 5-FU¼5-fluorouracil; HBP¼high blood pressure; RSA¼rectal–sigmoid adenocar-
cinoma.
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of administration and administration schedule may play a critical
role in its mechanism of action. Initially, 5-FU is inactive and is
converted, within cells, into various active nucleotide forms (Rose
et al, 2002): 5-fluoro-20-deoxyuridine-50-monophosphate (FdUMP)
is one of the critical nucleotide metabolites generated in tumour
cells and other sensitive tissues (Figure 1).
FdUMP potently inhibits thymidylate synthetase by competitive
binding, resulting in a thymine-depleted state (‘thymine-less death’).
This is enhanced by folate cofactors. Cytotoxic effects are also
mediated through the incorporation of fluorodeoxyuridine tripho-
sphate into DNA (seen in continuous 5-FU infusion), and of
fluorouridine-50-triphosphate (FUTP) and 5-fluorocytosine into
RNA (seen in bolus 5-FU). Furthermore, these metabolites are also
thought to alter membrane function (calcium channels), interfere
with mitochondrial metabolism (energy failure phosphate balance),
inhibit ribosomal RNA, alter macromolecule characteristics (con-
tractile elements), cause oxidative damage (pyrimidines are thought
to play a role in favism) and release of vasoactive substances
(histamine and catecholamines are known to cause ultrastructural
changes similar to doxorubicin toxicity) and induce autoimmune
activity (complexes between 5-FU cells or exposure of immunogenic
native compounds after cell damage) (Norwood et al, 1993).
The postulated causative mechanisms involved in 5-FU cardio-
toxicity are the following: an autoimmune response to damaged
cells; an increased oxygen demand in patients receiving 5-FU; a
coronary spasm caused by protein kinase C-mediated vasocon-
striction; dihydropyrimidine dehydrogenase deficiency (Milano
et al, 1999) and the 5-FU contaminant fluoroacetate. Inhibition of
DNA synthesis, due to 5-FU incorporation into myocardial cells,
was suggested to be the first step of cardiotoxicity and myocardial
depression has been explained by inhibition of mitochondrial DNA
synthesis due to 5-FU (Kohne et al, 1998). Furthermore, it has been
demonstrated that 5-FU may cause damage to endothelial cells
with consequent thrombus formation. In our experience, 5-FU-
associated effects on vascular endothelium reached their peak
about 3 days from initiation of treatment, which corresponds to
the clinical course of 5-FU cardiotoxicity (Cwikiel et al, 1995,
1996).
According to the analysis of 114 case reports, cardiotoxicity was
experienced in 61 vs 33% of patients who received 5-FU 12-h c.i. or
bolus 5-FU, respectively; 20% of the patients for whom data were
available had a history of coronary artery disease or some other
heart disease (Norbertus et al, 1993). Data do not support the
conclusion that dose and mode of administration of 5-FU therapy
may be an important factor in the development of cardiac toxicity
(Norwood et al, 1993). Data do not support the conclusion that a
history of cardiac disease increases the risks of 5-FU-induced
cardiotoxicity (Norbertus et al, 1993). CDDP frequently is
combined with 5-FU, and although a synergistic effect of CDDP
or carboplatin with 5-FU cannot be excluded, 5-FU therapy alone
could completely explain the toxicity observed. After the chest pain
appears, 5-FU treatment is usually discontinued and the response
to supportive treatment with nitrates or calcium-channel blockers
is good (Norbertus et al, 1993).
Many authors suggest that prophylaxis with cardioprotective
agents, after development of 5-FU-associated coronary ischaemia,
permits protracted 5-FU administration, where clinically indicated
(Oleksowicz and Bruckner, 1988; Norwood et al, 1993).
According to our experience, the average age of patients
was 64 years, none had a history of cardiac disease, but two
patients had HBP. Two patients were treated with combination
therapy regimens. Apparently, 5-FU administration modality did
not influence the angina-like pain presentation that appeared
approximately 95h after starting 5-FU therapy. The angina-like
syndrome disappeared with oral nitroglycerin and by stopping
infusion.
Since it was deemed necessary, 5-FU treatment was not
discontinued in our patients. For the two patients (Cases 1 and
2) receiving nocturnal 5-FU infusion in combination therapy, the
dose of 5-FU was reduced by 10–20% and patients were given
transepidermal nitroglycerine prophylaxis. 5-Fluorouracil admin-
istration modality was changed in the third patient (Case 3): the
bolus schedule (5-FU 370mgm
 2day
 1 plus FA 50mgtot
 1day
 1
for 5 days every 3 weeks) was modified to a weekly schedule (5-FU
450mgm
 2week
 1 and FA 100mgtot
 1week
 1), without prophy-
lactic therapy.
By taking the above-mentioned precautions, patients continued
therapy and no longer complained of acute angina-like pain.
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Figure 1 Fluorouracil metabolism: FUR¼fluorouridine; FUMP¼fluor-
fluorouridine-monophosphate; FUDP¼fluorouridine-diphosphate; FUTP¼
fluorouridine-triphosphate; dU¼deoxyuridine; 1¼uridine phosphorylase;
2¼uridine kinase; 3¼orotate phosphoribosyltransferase; 4¼thymidine
phosphorylase; 5¼thymidine kinase; 6¼thymidylate synthetase.
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